Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's 1Q2022
https://www.otcmarkets.com/otcapi/company/financial-report/334686/content
OTC PINK BASIC DISCLOSURE GUIDELINES
Key First Quarter 2022 and Subsequent Highlights
Revenue in the first quarter ended March 31, 2022 increased 682% to $27.0 million, as compared to revenue of $3.5 million in the first quarter of 2021
HENDERSON, NV / ACCESSWIRE/ May 25, 2022 / Solar Integrated Roofing Corp. (OTC PINK:SIRC), an integrated, single-source solar power, roofing systems installation and EV charging company, today provided a corporate update with recent highlights from its key divisions, while concurrently announcing record year-to-date sales of $110.0 million (preliminary, unaudited) as of May 20, 2022
110.0 YTD
-27.0 1Q2022
=83.0 in 2Q QTD
Are you telling me the sales are not real?
2Q Revenue at LEAST $83M. $110M through May-27M reported in 1Q
$MNMD Last7days, .77,.77,.80,.87,.90,.94,.99 that's some good MO
Ok, Wanda scares me a little. Just doing a small position for the conference pop
$MNMD: Now at .94 Before Jefferies Global Health care Conference. Presenting 6/10/2022 @12:45
Found one, $SIRC 110M Rev YTD, (5/20)
https://s3.amazonaws.com/b2icontent.irpass.cc/2474/rl108686.pdf
Profitable 1Q2022:
https://www.otcmarkets.com/otcapi/company/financial-report/334686/content
Net income of $5.6M on $26.99M revenue
Now Current on Financial Filings, Investor presentation notes submission for up listing.
In GSA program for EV charging stations
At LD Invitational next week June 6/7. Could move
1Q2022,10-Q. Real Sales,Real Profit
The OTC yield sign should come down soon with updated reporting
https://www.otcmarkets.com/otcapi/company/financial-report/334686/content
LD Micro Invitational XII next week, they are presenting
$SIRC Reports Record $110 Million inYearto-Date Sales
https://s3.amazonaws.com/b2icontent.irpass.cc/2474/rl108686.pdf
SolarIntegratedRoofing Corp. Provides Corporate Update, Reports Record $110 Million inYearto-Date Sales
Significant Increasein Sales Driven by Acquisitions and Robust Organic Growth
HENDERSON, NV / ACCESSWIRE/ May 25, 2022 / Solar Integrated Roofing Corp. (OTC PINK:SIRC), an integrated, single-source solar
power, roofing systems installation and EV charging company, today provided a corporate update with recent highlights from its key divisions,
while concurrently announcing record year-to-date sales of $110.0 million (preliminary, unaudited) as of May 20, 2022.
"The remarkable sales growth we have seen in 2022 as driven by effective marketing campaigns and strong operationalexecution across our
integrated family of companies," David Massey, Chief Executive Officer of Solar Integrated Roofing Corp. "Given our rapid pace of expansion, we
continue to believe our annualized sales run rate could potentially exceed $400 million by the end of 2022. Our focus to prioritize solar and EV
charging segment growth will further serve to supercharge our long-term potential - I look forward to continued operationalexecution in the
months ahead as we strive to create sustainable, long-term value for our shareholders and strive towards listing on a nationalexchange."
Recent Division Highlights
Roofing Division
Solar Integrated Roofing Corp.'s Roofing division experienced strong performance in the first half of 2022, with over 700 contracts signed year to
date. During a recent storm in Arkansas, the Roofing sales teams sold 120 roofs, demonstrating an effective sales, targeted strategy targeting
potentialcustomers during times of need. The Roofing division had preliminary unaudited year-to-date sales of $9.3 million as of May 20, 2022.
Residential Solar Division
The Residential Solar Division's dealer network now contains over 250 independent sales teams doing business in over 40 states across the
country. The division is currently projecting annual totals of 5,000 solar installs totaling over 30 megawatts for 2022. Residential Solar's
preliminary unaudited year-to-date sales were $44.4 million as of May 20, 2022.
Commercial Solar Division
The Company's Commercial Solar division sustained its momentum in 2022, receiving another $13 million in commercial projects in need of
development after a recent attendance at SolarCon, a leading industry conference. The division is currently working to provide an alternative
energy solution to granite yards throughout Southern California, and has also entered into a co-development agreement with Lux Power to provide
solar PPAs to over 15 Georgia schools. Preliminary unaudited year-to-date sales for the Commercial Solar Division were $39.3 million as of May
20, 2022.
Commercial Finance
The Commercial Finance division has over $190 million in projects from developers of alternative energy projects in need of financing solutions.
The division is also working with multiple banks to secure financing options for Solar Integrated Roofing Corp. to maintain ownership of
commercial projects. Recently, Commercial Finance developed a financing solution to assist churches across the country in desperate need of
relief from high electric bills with a no money out of pocket option to go solar. Commercial Finance had preliminary unaudited year-to-date sales of
$2.7 million as of May 20, 2022.
Boston Beer Company Introduces Cannabis-Infused Iced Teas
BOSTON, May 23, 2022 /PRNewswire/ -- The Boston Beer Company, Inc. (NYSE: SAM), maker of iconic, high-quality brands such as Samuel Adams, Truly Hard Seltzer and Twisted Tea, today announced the launch of TeaPot, a new line of cannabis-infused iced teas. TeaPot is the company's first infused beverage offering and will be available in select Canadian provinces beginning in July.
Good Day Iced Tea
Good Day Iced Tea
TeaPot blends real tea with specific cannabis strains to enhance specific times of the day. The brand's first release is a Good Day Iced Tea, made with real lemon black tea and infused with Pedro's Sweet Sativa, a unique cultivar which is grown in Strathroy, Ontario by licensed producer Entourage Health Corp. (TSXV: ENTG; OTCQX: ETRGF) and sold exclusively in Canada under its retail brand Color Cannabis. Each 12-ounce (355mL) can of TeaPot contains 5mg of THC and is crafted to minimize any cannabis taste or aroma. TeaPot will introduce additional varietals in the coming months.
"TeaPot purposefully pairs the right tea with the right pot for the right occasion," said Paul Weaver, Director, Head of Cannabis at The Boston Beer Company. "Each can is precisely dosed for social gatherings with friends and family. We think TeaPot is the best-tasting cannabis beverage on the market, and we can't wait for people to try it – we think they'll agree."
Since 2020, Canada's infused beverage market share has increased by nearly 850%[1], according to Headset retail data, and is approximately twice the size of the U.S. cannabis beverage market.
$ETRGF $SAM Boston beer using ERTGF in CannabisTEA
https://finance.yahoo.com/news/boston-beer-company-introduces-teapot-110000835.html
BOSTON, May 23, 2022 /PRNewswire/ -- The Boston Beer Company, Inc. (NYSE: SAM), maker of iconic, high-quality brands such as Samuel Adams, Truly Hard Seltzer and Twisted Tea, today announced the launch of TeaPot, a new line of cannabis-infused iced teas. TeaPot is the company's first infused beverage offering and will be available in select Canadian provinces beginning in July.
Good Day Iced Tea
Good Day Iced Tea
TeaPot blends real tea with specific cannabis strains to enhance specific times of the day. The brand's first release is a Good Day Iced Tea, made with real lemon black tea and infused with Pedro's Sweet Sativa, a unique cultivar which is grown in Strathroy, Ontario by licensed producer Entourage Health Corp. (TSXV: ENTG; OTCQX: ETRGF) and sold exclusively in Canada under its retail brand Color Cannabis. Each 12-ounce (355mL) can of TeaPot contains 5mg of THC and is crafted to minimize any cannabis taste or aroma. TeaPot will introduce additional varietals in the coming months.
"TeaPot purposefully pairs the right tea with the right pot for the right occasion," said Paul Weaver, Director, Head of Cannabis at The Boston Beer Company. "Each can is precisely dosed for social gatherings with friends and family. We think TeaPot is the best-tasting cannabis beverage on the market, and we can't wait for people to try it – we think they'll agree."
Since 2020, Canada's infused beverage market share has increased by nearly 850%[1], according to Headset retail data, and is approximately twice the size of the U.S. cannabis beverage market.
$MNMD announced results from the Phase 1 on to phase 2
NEW YORK, May 19, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers.
The results showed favorable safety and tolerability, support the advancement of MM-110, and have guided the Phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal. MM-110 (also known as zolunicant HCl or 18-MC) is an a3ß4 nicotinic cholinergic receptor antagonist and non-hallucinogenic proprietary congener of ibogaine.
"As there is a major unmet need to address the ongoing and ever-growing opioid crisis, we are very pleased with the results from our Phase 1 trial, which underscore the potential clinical utility of MM-110 to safely mitigate symptoms of opioid withdrawal," said Daniel R Karlin, MD MA, Chief Medical Officer of MindMed. "These data build on extensive pharmacology and toxicology studies, as well as encouraging results from preclinical studies that showed reductions in translational markers of opioid withdrawal and multi-day reductions in opioid self-administration following a single-dose administration of MM-110. Together, the data generated to date support our clinical development program and bring us one step closer to potentially providing an effective treatment solution with an optimized dosing schedule for withdrawal management. We look forward to leveraging these findings in the upcoming Phase 2a, gated two-part study, which will provide an opportunity for early signs of efficacy and inform the randomized proof-of-concept trial. The Phase 2a trial remains on track to initiate in the second quarter of 2022."
A total of 72 participants received up to 325 mg of MM-110 (n=51) twice on a single day or placebo (n=21), and 36 participants were administered up to 90mg of MM-110 (n=26) twice daily for seven days or placebo (n=10). The topline results and observations include the following:
MM-110 was well-tolerated up to 500mg per day in the single ascending dose (SAD) arm and 60 mg per day for seven days in the multiple-ascending dose (MAD) arm of the trial.
A linear pharmacokinetic profile was maintained across the tested doses and frequencies.
Observed clinical effects demonstrated alignment with potent CNS engagement.
No serious adverse events were reported. Treatment emergent adverse events were mild or moderate in severity and resolved without sequelae.
Clinical laboratory parameters and electrocardiograms were also assessed with no findings of clinical concern across the administered dose ranges.
Next steps: Consistent with the Phase 1 trial and aligned with the preclinical data, an every-other-day dose regimen is planned for the Phase 2a trial. This dose schedule offers the potential to be a better option than existing treatments for supervised opioid withdrawal.
About the Phase 1 Trial Design
The Phase 1 single and multiple-ascending dose trial conducted at a single clinical research site in Perth, Australia, evaluated the safety, tolerability, pharmacokinetics, and effects on the neurocognitive activity of MM-110 in 108 healthy volunteers.
From the CEO Letter:The acquired businesses collectively generated a revenue of $4.1 million and $1.4 million in adjusted EBITDA in 2020 & 2021, respectively, based on CF3's unaudited financials.
From the annual https://www.otcmarkets.com/otcapi/company/financial-report/326026/content
On March 7, 2022, the Company announced it had completed the acquisition of CF3 SPV I, LLC, ("CF3"), in an all-stock transaction. CF3's unit holders will receive convertible Series E Preferred shares. that will be valued between USD 250 to 550 million, subject to an audit and valuation being prepared by Stanton Park Advisors LLC. CF3 currently generates more than USD 28 million in annual revenue at its current run rate.
Could not find conversion ratio for series E
I Have issues .087x$7.30=$0.65. what am I missing
$SFIX I know its down, but still think it's a short. Jan Q should have been strong but was down from October. Not good for retailer.
$ETRGF Raised Revenue to$55.2M, 7%GM, BUT delayed again.
Blaming the auditors. Frustrating
Short Interest@4/14 1.2M=13.5% of float. NOT50%.
Got to call BS on that number
$ETRGF 4Q is going to be HUGE base on Premilitary Year end release
Entourage Health Announces Preliminary Fiscal Year 2021 Record Revenue of $54.8 Million with Q4and Full-Year earning call after the close 5/2/2022 • FYE2021 revenues up 54% over prior year due to record sales and expanded market share.
(I think Amounts in Canadian$)
Here a quick take, for 9 months they did $31.7M and reporting $54.8M for full year. So 4Q revenue should be $23.1M. 3Q revenue was only 14.9M. +55% Q/Q.
And they partner with Unions and Insurance companies for medical paid by insurance companies. (high margins)
Market cap of $24M trading at less than .5 sales, and grew sales +54% y/y
Under a collaboration with The Boston Beer Company subsidiary, Entourage is also the exclusive distributor of cannabis-infused beverages in Canada, expected to launch in 2022.
$MDGS see my posts of 2/7, 2/8, 2/9, 2/11, 2/14, 2/18, or 3/11.
There was too much good news and now it’s hitting the numbers.
Profitable, huge growth, and no debt
$MDGS GET IT NOW!!
TEL AVIV, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS) (“Medigus”), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, today reported financial results for the fiscal year ended December 31, 2021.
Key Highlights
Generated record revenues of $10.1 million for the full year 2021, representing an increase of $9.6 million, or 1,805%, compared to $0.5 million revenues in 2020
Net income reached a record $4 million in 2021, up from a net loss of $6.9 million in 2020
Cash and cash equivalents as of December 31, 2021 were $24 million, up from $22.4 million at year-end 2020
Shareholders’ equity attributed to Medigus improved 114% to $49 million in 2021, up from $23 million at year-end 2020
During 2022 the company expects to consolidate Gix Internet’s financial results. Gix Internet Revenues for 2021 amounted to approx. $45 million
$MDGS Revenue up 1,805%, $4M net income
TEL AVIV, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS) (“Medigus”), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, today reported financial results for the fiscal year ended December 31, 2021.
Key Highlights
Generated record revenues of $10.1 million for the full year 2021, representing an increase of $9.6 million, or 1,805%, compared to $0.5 million revenues in 2020
Net income reached a record $4 million in 2021, up from a net loss of $6.9 million in 2020
Cash and cash equivalents as of December 31, 2021 were $24 million, up from $22.4 million at year-end 2020
Shareholders’ equity attributed to Medigus improved 114% to $49 million in 2021, up from $23 million at year-end 2020
During 2022 the company expects to consolidate Gix Internet’s financial results. Gix Internet Revenues for 2021 amounted to approx. $45 million
Picked up some puts on $WE this week. House of cards, so much debt, cash burn, and HUGE share lockup expiring.
$ETRGF 4Q is going to be HUGE!
Entourage Health Announces Preliminary Fiscal Year 2021 Record Revenue of $54.8 Million with Q4and Full-Year 2021 Financials to be filed by MAY 3, 2022•
FYE2021 revenues up 54% over prior year due to record sales and expanded market share.
(I think Amounts in Canadian$)
Here a quick take, for 9 months they did $31.7M and reporting $54.8M for full year. So 4Q revenue should be $23.1M. 3Q revenue was only 14.9M. +55% Q/Q.
And, They partner with Unions and Insurance companies for medical paid by insurance companies. (high margins)
Market cap of $24M trading at less than .5 sales, and grew sales +54% y/y
Under a collaboration with The Boston Beer Company subsidiary, Entourage is also the exclusive distributor of cannabis-infused beverages in Canada, expected to launch in 2022.
$SPOK, 17%-Yield! $43M cash, no debt. Should be free cash flow positive in next 2 quarters.
Melting ice cube pager business, and newer software systems for hospitals
Equity Markets closed on Friday. and no options expirations for 4/15.
How many fake accounts are on twitter?
Carnegie Mellon University
https://www.cmu.edu/news/stories/archives/2020/may/twitter-bot-campaign.html
Encountering a bot account while scrolling through Twitter is more likely to occur in the era of COVID-19. Carnegie Mellon University researchers have discovered that much of the discussion around the pandemic and stay-at-home orders is being fueled by misinformation campaigns that use convincing bots.
To analyze bot activity around the pandemic, CMU researchers since January have collected more than 200 million tweets discussing coronavirus or COVID-19. Of the top 50 influential retweeters, 82% are bots, they found. Of the top 1,000 retweeters, 62% are bots.
$VALE Tesla signed secret nickel supply deal with Vale - Bloomberg News
https://finance.yahoo.com/news/1-tesla-signed-secret-nickel-134838646.html
$ETRGF 4Q is going to be HUGE!
Entourage Health Announces Preliminary Fiscal Year 2021 Record Revenue of $54.8 Million with Q4and Full-Year 2021 Financials to be filed by April 1, 2022• FYE2021 revenues up 54% over prior year due to record sales and expanded market share.
(Amounts in Canadian$) Here a quick take, for 9 months they did $31.7M and reporting $54.8M for full year. So 4Q revenue should be $23.1M. 3Q revenue was only 14.9M. +55% Q/Q.
And, They partner with Unions and Insurance companies for medical paid by insurance companies.
Market cap of $24M trading at less than .5 sales, and grew sales +54% y/y
3/22/2022 Cresco Labs buying Columbia Care for about $2B, and company guidance revenue for CCHWF, is $473M so paying 4.2x revenue
$KOPN from 2.10 to 2.85 in 5 days. Also higher volumes. And there are a lot of open interest near and long calls
$ETRGF: Canadian Cannabis, 55% Q/Q revenue growth
Here a quick take, for 9 months they did 31.7M and reporting preliminary $54.8M for full year. So 4Q revenue should be 23.1M 3Q revenue was only 14.9M. +55% Q/Q.
Will report April 1st.
Market cap of 24M trading at less than .5 sales, and grew sales +54% y/y
Entourage Health Announces Preliminary Fiscal Year 2021 Record Revenue of $54.8 Million with Q4and Full-Year 2021 Financials to be filed by April 1, 2022• FYE2021 revenues up 54% over prior year due to record sales and expanded market share.
And, They partner with Unions and Insurance companies for medical paid by insurance companies.
Are there Better charging systems?
Planned Spin-Off and Subsequent Merger of its EV Wireless
Medigus Announces Details of Planned Spin-Off and Subsequent Merger of its EV Wireless Charging Business
Friday, March 11, 2022 01:55:07 PM (GMT)
Charging Robotics signs LOI to complete reverse merger on OTC Markets
Tel Aviv, Israel, March 11, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that the Company and its wholly owned subsidiary, Charging Robotics Ltd., signed a non-binding letter of intent for a planned securities exchange agreement with Fuel Doctor, Inc. (OTC: FDOC), a Delaware corporation traded on the OTC Markets. The securities exchange agreement, if signed, will be subject to customary closing conditions.
The transaction will result in Charging Robotics becoming a wholly owned subsidiary of Fuel Doctor, and in exchange, Medigus will receive 80% of the issued and outstanding share capital of Fuel Doctor.
Upon closing, Medigus will appoint nominees as officers and directors of Fuel Doctor. As of the closing, FDOC shall have net cash in an amount of no less than $1.0 million, excluding Fuel Doctor’s expenses in connection with the contemplated transaction.
Charging Robotics is transforming the way electric vehicles are charged using its robotic platform to deliver automatic wireless charging. At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer energy wirelessly from the robot to the vehicle.
The robotic platform is small enough to fit under vehicles, automatically positioning itself for maximum charging efficiency and returning to its docking station at the end of the charging operation. Once fully developed, Charging Robotics plans to install the system in public parking lots, providing a solution that dramatically lowers EV charging infrastructure installation costs relative to current alternatives.
About Charging Robotics
Charging Robotics is developing an automatic wireless charging system dedicated for public parking lots. The benefit of the robotic wireless charging system is that it will automatically align with high accuracy the energy transmitting device to the onboard energy receiving device thus allowing for very high charging efficiencies. The system will be fully automatic, thus eliminating the need for the driver to remove the car after charging is complete, which will increase the charger utilization and profits for the parking lot operator.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle markets. Medigus' affiliations in the medical solutions arena include ownership in Polyrizon Ltd. and ownership in industry 4.0 company, ScoutCam Inc. The Company’s affiliates in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd. and Revoltz Ltd. are also part of the Company’s portfolio of technology solution providers. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/.
Forward-Looking Statements
$MDGS Planned Spin-Off-Subsequent Merger of its EV Wireless
Medigus Announces Details of Planned Spin-Off and Subsequent Merger of its EV Wireless Charging Business
Friday, March 11, 2022 01:55:07 PM (GMT)
Charging Robotics signs LOI to complete reverse merger on OTC Markets
Tel Aviv, Israel, March 11, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that the Company and its wholly owned subsidiary, Charging Robotics Ltd., signed a non-binding letter of intent for a planned securities exchange agreement with Fuel Doctor, Inc. (OTC: FDOC), a Delaware corporation traded on the OTC Markets. The securities exchange agreement, if signed, will be subject to customary closing conditions.
The transaction will result in Charging Robotics becoming a wholly owned subsidiary of Fuel Doctor, and in exchange, Medigus will receive 80% of the issued and outstanding share capital of Fuel Doctor.
Upon closing, Medigus will appoint nominees as officers and directors of Fuel Doctor. As of the closing, FDOC shall have net cash in an amount of no less than $1.0 million, excluding Fuel Doctor’s expenses in connection with the contemplated transaction.
Charging Robotics is transforming the way electric vehicles are charged using its robotic platform to deliver automatic wireless charging. At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer energy wirelessly from the robot to the vehicle.
The robotic platform is small enough to fit under vehicles, automatically positioning itself for maximum charging efficiency and returning to its docking station at the end of the charging operation. Once fully developed, Charging Robotics plans to install the system in public parking lots, providing a solution that dramatically lowers EV charging infrastructure installation costs relative to current alternatives.
About Charging Robotics
Charging Robotics is developing an automatic wireless charging system dedicated for public parking lots. The benefit of the robotic wireless charging system is that it will automatically align with high accuracy the energy transmitting device to the onboard energy receiving device thus allowing for very high charging efficiencies. The system will be fully automatic, thus eliminating the need for the driver to remove the car after charging is complete, which will increase the charger utilization and profits for the parking lot operator.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle markets. Medigus' affiliations in the medical solutions arena include ownership in Polyrizon Ltd. and ownership in industry 4.0 company, ScoutCam Inc. The Company’s affiliates in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd. and Revoltz Ltd. are also part of the Company’s portfolio of technology solution providers. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/.
Forward-Looking Statements
Nickle Halted on LME, See $JJN
Russia Fake News law, Can TWTR employees go to jail?
$SPOK 14% yield, NoDebt, $59M cash
Just raised dividend 150%.
Business model struggling, Huge expense reduction plan in process.
Brandon Getting Tuff on Russia, Unfollows on Twitter
:)
When will Android Truth Social be launched?
Just another nail for TWTR;
Here’s a few things that make me nervous about TWTR. A few copy and pastes from the earnings release.
Total revenue was $1.57 billion in Q4
Total ad engagements decreased 12% due to a mix shift toward lower funnel ad formats
Total costs and expenses (including cost of revenue and all operating expenses) grew to $1.40 billion in Q4. Expense growth of 35%
Research and development expenses grew 50%
Sales and marketing expenses grew 39%
General and administrative expenses increased 55%
Outlook
For Q1’22, we expect:
•Total revenue to be between $1.17 billion and $1.27 billion.
•GAAP operating loss to be between $225 million and $175 million
So Management guides Revenue down between $300-$400 Million, and 4Q Expense growth was off the charts. Drawing on Credit facilities to fund accelerated share repurchase so interest expense will be higher, (and rates are going up, just ask the FED)